Amgen Inc. $AMGN Shares Bought by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 24.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 21,499 shares of the medical research company’s stock after acquiring an additional 4,166 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Amgen were worth $7,037,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Dogwood Wealth Management LLC lifted its holdings in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the period. Anfield Capital Management LLC lifted its holdings in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the last quarter. Board of the Pension Protection Fund bought a new position in shares of Amgen during the 4th quarter valued at about $26,000. Manning & Napier Advisors LLC grew its stake in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC acquired a new stake in Amgen during the fourth quarter valued at approximately $33,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a planned CFO transition, with Peter Griffith retiring and Thomas Dittrich returning to the company to succeed him. A well-telegraphed succession plan can reduce uncertainty around finance leadership and is typically viewed as a stability signal. AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
• Neutral Sentiment: Amgen also named an analyst report in the news flow, along with Piper Sandler trimming its price target while keeping an Overweight rating. That suggests continued long-term optimism, but the target cut is a modest headwind rather than a major catalyst. Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism
• Negative Sentiment: Separately, Amgen’s kidney disease drug Tavneos faced renewed scrutiny in Japan, where partner Kissei urged doctors to use caution and avoid starting new patients amid safety and regulatory concerns. Headlines like this can pressure sentiment because they raise questions about the product’s commercial trajectory and safety profile. Amgen Japanese Partner Urges Caution On Tavneos Use

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Wells Fargo & Company lifted their target price on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Deutsche Bank Aktiengesellschaft increased their price target on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Argus lifted their price target on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Rothschild & Co Redburn upped their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Finally, Morgan Stanley set a $332.00 target price on shares of Amgen in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $356.15.

Amgen Price Performance

NASDAQ AMGN opened at $330.75 on Wednesday. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The stock’s 50-day moving average is $347.53 and its two-hundred day moving average is $343.86. The firm has a market cap of $178.50 billion, a P/E ratio of 23.02, a price-to-earnings-growth ratio of 3.26 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.15%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.85% of the stock is currently owned by corporate insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.